Trials / Terminated
TerminatedNCT06630247
A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors
A Dose-escalation, Dose-finding, and Expansion Study of XL495 as a Single Agent and in Combination Therapy in Participants With Locally Advanced or Metastatic Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Exelixis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to obtain safety, tolerability, PK, and preliminary clinical antitumor activity for XL495 as a single agent and in combination with select cytotoxic agents in participants with locally advanced or metastatic tumors for whom life-prolonging therapies do not exist or available therapies are intolerable/no longer effective.
Conditions
- Solid Cancers
- Solid Tumor Cancer
- Solid Tumor Malignancy
- Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
- Metastatic Solid Tumor
- Locally Advanced Solid Tumor
- Urothelial Cancer of Renal Pelvis
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XL495 | oral doses of XL495 |
| DRUG | ADC cytotoxic agents | intravenous infusion of anti-cancer combination agent |
Timeline
- Start date
- 2024-10-17
- Primary completion
- 2025-05-07
- Completion
- 2025-05-07
- First posted
- 2024-10-08
- Last updated
- 2025-06-25
Locations
10 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06630247. Inclusion in this directory is not an endorsement.